Showing results (221-230 of 438) with videos related to

Sort By:
Pageof 44
Cytotherapy|November 27, 2022
Allogeneic cord blood regulatory T cells can resolve lung inflammationMi-Ae Lyu, Meixian Huang, Ke Zeng, et al.
Blood Advances|March 19, 2024
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinibJavid J Moslehi, Richard R Furman, Constantine S Tam, et al.
Parasites & Vectors|November 28, 2023
Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto® Chew (25 mg/kg fluralaner) or Simparica TRIO® (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)Kathryn E Reif, Naemi P Bickmeier, Brian H Herrin, et al.
BMC Veterinary Research|October 30, 2022
Satisfactory breeding potential is transiently eliminated in beef bulls with clinical anaplasmosisAnne C Lovett, Emily J Reppert, John R Jaeger, et al.
Southern Medical Journal|October 6, 2016
Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma IncidenceCatherine Bulka, Loretta J Nastoupil, Jean L Koff, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2015
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaChristopher R Flowers, Jennifer R Brown, Hilary Rosenthal, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 24, 2015
Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphomaChristine C Davis, Jonathon B Cohen, Katherine S Shah, et al.
Leukemia & Lymphoma|September 30, 2014
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United StatesLoretta J Nastoupil, Rajni Sinha, Michelle Byrtek, et al.
American Journal of Hematology|May 3, 2024
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphomaSam Yuen, Tycel J Phillips, Rajat Bannerji, et al.
Current Medical Research and Opinion|October 8, 2024
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trialJudith Trotman, Pier Luigi Zinzani, Yuqin Song, et al.
Pageof 44